Clinical Trial: A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439510) titled 'A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants' on Feb. 18.

Brief Summary: This Phase 2b/3, randomized, double-blind, placebo-controlled, 2-part study will evaluate the efficacy, safety and tolerability of different dose regimens of SPG601 in adult male participants with Fragile X syndrome.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Fragile X Syndrome (FXS)

Intervention: DRUG: SPG601

synthetic small molecule

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Spinogenix

Disclaimer: Curated by HT Syndication....